Skip to main content

News


A student of the "Joves i Ciència" Programme joins the group

Last July, we hosted Emma Catini, a participant from the "Joves i Ciència" programme by Fundació Catalunya La Pedrera. She had the opportunity to collaborate with our students developing biomaterials for oncological applications.

Congratulations to Dr. Marc Martínez-Miguel!

Marc Martínez-Miguel successfully defended his PhD thesis titled " Nanoparticles to modulate topography and ligand distribution at the nanoscale: impact on cell behavior" on Thursday, 9 March 2023. Congratulations!

Eduardo Pérez participates at "Transfiere - 12th European Meeting on Science, Technology and Innovation"

Eduardo Pérez presents our biohybrid hydrogels at “Transfiere 2023” and explains their potential use as artificial extracellular matrices for applications related to cancer.

"YouMaker: así se hace la Ciencia” – Judith Guasch & Ignacio Crespo

Judith Guasch participates in the project “YouMaker: así se hace la Ciencia” of ICMAB-CSIC.

Congratulations to Dr. Roberto Fabião Santos Abreu!

Roberto Fabião Santos Abreu successfully defended his PhD thesis titled "Natural and Synthetic Hydrogels as Biomimetic Materials for Cancer Immunotherapies" on Thursday, 21 April 2022. Congratulations!

Judith Guasch interviewed at "Penedes TV”

On 11 March 2022, ICMAB researcher Judith Guasch was interviewed at Penedes TV  in the program “Trobades al Vinseum” by the  journalist Judit Benages. Judith was asked about her experience and developments in the field of biomaterials for cancer immunotherapy.

Eduardo Pérez del Río receives an award for the best publications of 2020 by CIBER-BBN

Nanomol researcher Eduardo Pérez del Río has been awarded with one of the 4 prices for the best publications of 2020 of young researchers by CIBER-BBN.

Judith Guasch talks about her personal experience as a scientist and her research in the “Cicle Ciència i Futur”

On 24 October 2021, Llorenç Rafecas, founder of the pharmaceutical company Enantia and President of “El Centre”, interviewed ICMAB researcher Judith Guasch in the framework of the “Cicle de Ciència i Futur” organized by “El Centre”; a cultural center of Llorenç del Penedès. Judith explained her personal experience as a researcher and her developments in the field of biomaterials for cancer immunotherapy.

Judith Guasch in "Penedès en Xarxa" on the occasion of the International Breast Cancer Awareness Day

On Monday, 9 October 2021, ICMAB Researcher Judith Guasch was interviewed in the program “Penedes en Xarxa” broadcasted by Domenys Ràdio, Canal 20 Olèrdola, Ràdio Sant Sadurní i Ràdio Vilafranca on the ocasion of the International Breast Cancer Awareness Day. She talked about cancer immunotherapy and how her research on biomaterials can be meaningful to these novel treatments.

Our cancer research at the new issue of the "CSIC Investiga" magazine

Judith Guasch and her group at the Nanomol unit are focusing on the development of hydrogels for the culture of T cells used for cancer immunotherapy through the adoptive cellular therapy. This therapy is based on reinforcing and multiplying T cells of the own body. The idea is to create 3D hydrogel structures that imitate the lymph nodes where T cell proliferate, to grow and modify them and introduce them back to the body.

Judith Guasch in Onda Cero Radio: mimicking lymph-nodes to proliferate T cells

Judith Guasch is interviewed in Onda Cero Radio on 21 November 2020 in the programme "De cero al infinito" con Paco de León, to talk about her recent research on hydrogels to mimic lymph nodes for cancer immunotherapy. 

Fourth visit of the Scientific Advisory Board at ICMAB - online!

On 3-4 December 2020, the ICMAB Scientific Advisory Board (SAB) meeting will take place to evaluate the research lines and the overall performance of the Institute. The SAB is composed of 12 worldwide scientific experts in the areas of the targeted research of our Severo Ochoa project: Smart Functional Materials for a Better Future (FUNFUTURE) in the areas of Clean Energy, Sustainable Electronics and Smart Nanomedicine.

Judith Guasch talks about biomimetics and cancer immunotheraphy in CosmoCaixa Live Talks

On 18 November 2020, Valentina Raffio, science journalist, interviewed ICMAB researcher at the Nanomol Group Judith Guasch in the framework of the CosmoCaixa Live Talks organized by CosmoCaixa and the Catalan Association of Science Communication (ACCC). The event took place online on CosmoCaixa Facebook Live and is now available online.

Judith Guasch interviewed in Agencia SINC for the 3D hydrogels used in cancer immunotherapy

On 9 November 2020, Judith Guasch appered in the cover of the Agencia SINC in an interview to talk about her research on 3D hydrogels that mimic lymph nodes and that will be used as scaffolds for T cell culture in cancer immunotherapy.

Judith Guasch talks about T cell growth-inducing 3D hydrogels on RNE

On Sunday, 13 September 2020, ICMAB Researcher Judith Guasch appeared on the RNE radio program “A hombros de Gigantes” to talk about the newly designed 3D hydrogels that can help in Adoptive Cell Therapy (ACT) for cancer.

Congratulations to Dr. Eduardo Pérez del Río!

Eduardo Pérez del Río successfully defended his PhD thesis titled "3D Systems for immune cells culture and their applications in Immunotherapy " on Thursday, 2 April 2020. Congratulations!

Judith Guasch is awarded with a Ramón y Cajal grant #RYC

ICMAB researcher Judith Guasch has been granted with a Ramón y Cajal grant from the Spanish Ministry of Economy, Industry and Competitiveness in the branch of “Biomedicine”.

Judith Guasch, awarded with a leader position of a Max Planck Partner Group

The ICMAB researcher Judith Guasch has been appointed Leader of a Max Planck Partner Group (Dynamic Biomimetics for Cancer Immunotherapy) in collaboration with the Max Planck Institute for Medical Research (Heidelberg, Germany). This position, started this same 2017, strengthens the collaboration of ICMAB with the Max Planck Society through the research that Judith is performing, which is based on the development of biomimetic lymph nodes to help improving novel adoptive cell therapies, specially those designed to treat cancer.